Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Daily Magnesium-supplement for Severe Asthmatics

This study has been completed.
Gunnar Kjems APS
GCP-unit at Aarhus University Hospital, Aarhus, Denmark
Aarhus University Hospital
Information provided by (Responsible Party):
University of Aarhus Identifier:
First received: April 27, 2010
Last updated: September 3, 2013
Last verified: September 2013

The present study is part of a project titled 'Magnesium in asthma and chronic obstructive pulmonary disease'. The hypothesis of the main project is that a daily magnesium supplement will benefit patients with asthma and chronic obstructive pulmonary disease.

The aim of this part of the project is to reveal possible beneficial effects of daily magnesium supplement for severe asthmatics, refractory to conventional treatment.

Condition Intervention
Dietary Supplement: Mablet (Magnesium-supplement)
Other: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Daily Magnesium-supplement With Mablet for Steroid-resistant, Severe Asthmatics

Resource links provided by NLM:

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Asthma control test (ACT) [ Time Frame: Two years ]
    Questionnaire providing a level of disease control

Secondary Outcome Measures:
  • EQ-5D [ Time Frame: Two years ]
    Questionnaire providing a degree of quality of life

  • Spirometry [ Time Frame: Two years ]
    Lung function testing

  • Reversibility testing [ Time Frame: Two years ]
    Lung function reversibility testing with beta2-agonists

  • Diary [ Time Frame: Two years ]
    Participants will register asthma symptoms, use of reliever medication and exacerbations

  • Adverse effects [ Time Frame: Two years ]
  • Blood- and urine samples [ Time Frame: Two years ]
    Se-magnesium, dU-magnesium, se-creatinin, se-potassium, se-sodium, se-albumine, se-Ca2+, se-phosphate, dU-Ca and dU-creatinine

  • Endogen NO in expiratory breath and Impulse Oscillometry. [ Time Frame: Two years ]

Enrollment: 5
Study Start Date: April 2011
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Washout
Active Comparator: Mablet Dietary Supplement: Mablet (Magnesium-supplement)
3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
Other Name: Mablet
Placebo Comparator: Placebo Other: Placebo
3 placebo tablets daily for 12 weeks


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • severe asthmatics, refractory to conventional treatment, including systemic steroid treatment; symptoms must be annual.

Exclusion Criteria:

  • Se-Mg > 2,00 mmol/L,
  • smoking cessation less than 1 year prior to study start,
  • major changes in eating habits within three months prior to study start and during the study period of approximately one year,
  • various conditions (e.g. gastrointestinal disease, kidney disease, pregnancy/lactation) that may affect the study results.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01113151

Research Dept. of Respiratory Medicine, Aarhus University Hospital
Aarhus C, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
Gunnar Kjems APS
GCP-unit at Aarhus University Hospital, Aarhus, Denmark
Aarhus University Hospital
Principal Investigator: Ronald Dahl, Professor Dept. of Respiratory Medicine, Aarhus University Hospital, Denmark
  More Information


Responsible Party: University of Aarhus Identifier: NCT01113151     History of Changes
Other Study ID Numbers: 9727c
Study First Received: April 27, 2010
Last Updated: September 3, 2013

Keywords provided by University of Aarhus:
Severe asthmatics
Annual symptoms
Daily magnesium supplement
ACT (asthma control test)

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases processed this record on May 22, 2017